创新-话题@MedSci

#创新#

1015篇内容 | 8077人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1286050, encodeId=6285128605055, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=3. 何为原始创新？, objectType=article, longId=220081, objectId=041e220081ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=041e220081ce, replyNumber=0, likeNumber=0, createdTime=2021-11-12, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=041e220081ce, moduleTitle=3. 何为原始创新？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=041e220081ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286046, encodeId=86f5128604679, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=英国批准默沙东新冠口服药物molnupiravir，开创新冠治疗的新时代！, objectType=article, longId=219813, objectId=f9052198134a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9052198134a, replyNumber=0, likeNumber=83, createdTime=2021-11-06, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9052198134a, moduleTitle=英国批准默沙东新冠口服药物molnupiravir，开创新冠治疗的新时代！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9052198134a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286045, encodeId=3dfd1286045a4, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=2021年11月1日简报：张文宏就上海迪士尼防疫情况发声；日本疫情惊人骤减，日增从2.5万下降至200例；白宫发言人普萨基确诊新冠；新加坡与病毒共存后，新增确诊不断创新高, objectType=article, longId=219594, objectId=323a21959493, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=323a21959493, replyNumber=0, likeNumber=65, createdTime=2021-11-02, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=323a21959493, moduleTitle=2021年11月1日简报：张文宏就上海迪士尼防疫情况发声；日本疫情惊人骤减，日增从2.5万下降至200例；白宫发言人普萨基确诊新冠；新加坡与病毒共存后，新增确诊不断创新高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=323a21959493)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286044, encodeId=deaf12860445d, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=2021第五届中国数字医疗创新峰会在沪举行，梅斯医学共话数字化营销新趋势, objectType=article, longId=219440, objectId=a3ce219440d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3ce219440d6, replyNumber=0, likeNumber=81, createdTime=2021-10-30, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3ce219440d6, moduleTitle=2021第五届中国数字医疗创新峰会在沪举行，梅斯医学共话数字化营销新趋势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3ce219440d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286043, encodeId=ae12128604377, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=这几种临床试验的创新策略你知道吗？, objectType=article, longId=219283, objectId=f48221928344, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f48221928344, replyNumber=0, likeNumber=27, createdTime=2021-10-28, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f48221928344, moduleTitle=这几种临床试验的创新策略你知道吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f48221928344)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286042, encodeId=e15a128604283, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=会议推荐 | 「全链重构」第八届N·GS创新开发者大会2021开启啦！, objectType=article, longId=218604, objectId=676121860477, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=676121860477, replyNumber=0, likeNumber=62, createdTime=2021-10-16, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=676121860477, moduleTitle=会议推荐 | 「全链重构」第八届N·GS创新开发者大会2021开启啦！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=676121860477)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286041, encodeId=1a991286041d6, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=糖尿病创新药iGlarLixi中国III期临床试验达到主要有效性终点, objectType=article, longId=218304, objectId=0e0c218304c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e0c218304c9, replyNumber=0, likeNumber=67, createdTime=2021-10-11, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e0c218304c9, moduleTitle=糖尿病创新药iGlarLixi中国III期临床试验达到主要有效性终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e0c218304c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286040, encodeId=bd6f1286040db, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=国家药品监督管理局正式受理糖尿病创新药iGlarLixi上市申请, objectType=article, longId=217851, objectId=e17e21e8517a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e17e21e8517a, replyNumber=0, likeNumber=82, createdTime=2021-09-30, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e17e21e8517a, moduleTitle=国家药品监督管理局正式受理糖尿病创新药iGlarLixi上市申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e17e21e8517a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286039, encodeId=3a541286039aa, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=半数重症肌无力患者在黄金年龄发病，创新疗法有望带来突破, objectType=article, longId=217782, objectId=d4ce21e78213, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4ce21e78213, replyNumber=0, likeNumber=84, createdTime=2021-09-29, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4ce21e78213, moduleTitle=半数重症肌无力患者在黄金年龄发病，创新疗法有望带来突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4ce21e78213)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286038, encodeId=8e041286038c4, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=纳入优先审评！恒瑞医药创新药吡咯替尼新适应症——新辅助治疗, objectType=article, longId=217708, objectId=bfcd21e7083b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfcd21e7083b, replyNumber=0, likeNumber=71, createdTime=2021-09-28, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfcd21e7083b, moduleTitle=纳入优先审评！恒瑞医药创新药吡咯替尼新适应症——新辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfcd21e7083b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286037, encodeId=e15d128603eb6, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=创新策源，共享开放|张江生命科学国际创新峰会即将开启, objectType=article, longId=217431, objectId=b31b21e43116, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b31b21e43116, replyNumber=0, likeNumber=61, createdTime=2021-09-24, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b31b21e43116, moduleTitle=创新策源，共享开放|张江生命科学国际创新峰会即将开启, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b31b21e43116)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286036, encodeId=38e612860365c, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=15亿美元再下赌注！中国生物制药创新如何扬帆破浪？, objectType=article, longId=217307, objectId=e70321e30778, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e70321e30778, replyNumber=0, likeNumber=76, createdTime=2021-09-20, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e70321e30778, moduleTitle=15亿美元再下赌注！中国生物制药创新如何扬帆破浪？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e70321e30778)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286035, encodeId=474a1286035f9, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=显著减轻疼痛并改善功能骨关节炎创新疗法3期临床结果积极, objectType=article, longId=217282, objectId=829521e282c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=829521e282c1, replyNumber=0, likeNumber=73, createdTime=2021-09-20, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=829521e282c1, moduleTitle=显著减轻疼痛并改善功能骨关节炎创新疗法3期临床结果积极, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=829521e282c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286055, encodeId=571f12860552e, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=杨森中国又有4个创新药被纳入国家医保目录，6个产品成功续约, objectType=article, longId=217202, objectId=c93d21e20202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c93d21e20202, replyNumber=0, likeNumber=68, createdTime=2021-09-18, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c93d21e20202, moduleTitle=杨森中国又有4个创新药被纳入国家医保目录，6个产品成功续约, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c93d21e20202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286034, encodeId=4ef91286034c0, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=RNA修饰创新研究设计-m6A甲基化的测序方法？, objectType=article, longId=216871, objectId=47242168e1bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47242168e1bb, replyNumber=0, likeNumber=67, createdTime=2021-09-11, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47242168e1bb, moduleTitle=RNA修饰创新研究设计-m6A甲基化的测序方法？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47242168e1bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286033, encodeId=fcbf1286033e7, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=创新细胞治疗公司士泽生物完成近亿元Pre-A轮融资，启明创投和礼来亚洲基金共同领投, objectType=article, longId=216834, objectId=97d921683481, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97d921683481, replyNumber=0, likeNumber=88, createdTime=2021-09-10, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97d921683481, moduleTitle=创新细胞治疗公司士泽生物完成近亿元Pre-A轮融资，启明创投和礼来亚洲基金共同领投, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97d921683481)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286032, encodeId=f922128603235, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=安帝康生物抗流感1类新药在中国获批临床，加速抗感染领域创新药研发, objectType=article, longId=216782, objectId=9260216e829f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9260216e829f, replyNumber=0, likeNumber=67, createdTime=2021-09-09, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9260216e829f, moduleTitle=安帝康生物抗流感1类新药在中国获批临床，加速抗感染领域创新药研发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9260216e829f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286056, encodeId=e7e61286056db, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=杨森制药聚焦数据科学，助力中国药物和医疗创新, objectType=article, longId=216576, objectId=7b9a2165e622, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b9a2165e622, replyNumber=0, likeNumber=69, createdTime=2021-09-03, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b9a2165e622, moduleTitle=杨森制药聚焦数据科学，助力中国药物和医疗创新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b9a2165e622)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286031, encodeId=5c4a12860311b, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=京新药业与韩国B-PS公司达成合作，引进癫痫First in Class创新药, objectType=article, longId=216391, objectId=d21b216391ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d21b216391ec, replyNumber=0, likeNumber=85, createdTime=2021-08-29, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d21b216391ec, moduleTitle=京新药业与韩国B-PS公司达成合作，引进癫痫First in Class创新药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d21b216391ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286030, encodeId=d4f412860309d, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=2021年8月27日简报：国产新冠灭活疫苗对德尔塔毒株保护率为59％；日本和越南疫情再创新高；美国发现未打疫苗者因新冠住院概率是已获保护者29倍, objectType=article, longId=216376, objectId=cc662163e6a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc662163e6a2, replyNumber=0, likeNumber=58, createdTime=2021-08-28, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc662163e6a2, moduleTitle=2021年8月27日简报：国产新冠灭活疫苗对德尔塔毒株保护率为59％；日本和越南疫情再创新高；美国发现未打疫苗者因新冠住院概率是已获保护者29倍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc662163e6a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

创新

2020-05-29

lilianxiang (审核中...)

前往app查看评论内容

#创新#

3. 何为原始创新？

2021-11-12

lilianxiang (审核中...)

前往app查看评论内容

#创新#

英国批准默沙东新冠口服药物molnupiravir，开创新冠治疗的新时代！

2021-11-06

lilianxiang (审核中...)

前往app查看评论内容

#创新#

2021年11月1日简报：张文宏就上海迪士尼防疫情况发声；日本疫情惊人骤减，日增从2.5万下降至200例；白宫发言人普萨基确诊新冠；新加坡与病毒共存后，新增确诊不断创新高

2021-11-02

lilianxiang (审核中...)

前往app查看评论内容

#创新#

2021第五届中国数字医疗创新峰会在沪举行，梅斯医学共话数字化营销新趋势

2021-10-30

lilianxiang (审核中...)

前往app查看评论内容

#创新#

这几种临床试验的创新策略你知道吗？

2021-10-28

lilianxiang (审核中...)

前往app查看评论内容

#创新#

会议推荐 | 「全链重构」第八届N·GS创新开发者大会2021开启啦！

2021-10-16

heli0118 (审核中...)

前往app查看评论内容

#创新#

糖尿病创新药iGlarLixi中国III期临床试验达到主要有效性终点

2021-10-11

lilianxiang (审核中...)

前往app查看评论内容

#创新#

国家药品监督管理局正式受理糖尿病创新药iGlarLixi上市申请

2021-09-30

lilianxiang (审核中...)

前往app查看评论内容

#创新#

半数重症肌无力患者在黄金年龄发病，创新疗法有望带来突破

2021-09-29

lilianxiang (审核中...)

前往app查看评论内容

#创新#

纳入优先审评！恒瑞医药创新药吡咯替尼新适应症——新辅助治疗

2021-09-28

lilianxiang (审核中...)

前往app查看评论内容

#创新#

创新策源，共享开放|张江生命科学国际创新峰会即将开启

2021-09-24

lilianxiang (审核中...)

前往app查看评论内容

#创新#

15亿美元再下赌注！中国生物制药创新如何扬帆破浪？

2021-09-20

lilianxiang (审核中...)

前往app查看评论内容

#创新#

显著减轻疼痛并改善功能骨关节炎创新疗法3期临床结果积极

2021-09-20

lilianxiang (审核中...)

前往app查看评论内容

#创新#

杨森中国又有4个创新药被纳入国家医保目录，6个产品成功续约

2021-09-18

lilianxiang (审核中...)

前往app查看评论内容

#创新#

RNA修饰创新研究设计-m6A甲基化的测序方法？

2021-09-11

lilianxiang (审核中...)

前往app查看评论内容

#创新#

创新细胞治疗公司士泽生物完成近亿元Pre-A轮融资，启明创投和礼来亚洲基金共同领投

2021-09-10

lilianxiang (审核中...)

前往app查看评论内容

#创新#

安帝康生物抗流感1类新药在中国获批临床，加速抗感染领域创新药研发

2021-09-09

lilianxiang (审核中...)

前往app查看评论内容

#创新#

杨森制药聚焦数据科学，助力中国药物和医疗创新

2021-09-03

lilianxiang (审核中...)

前往app查看评论内容

#创新#

京新药业与韩国B-PS公司达成合作，引进癫痫First in Class创新药

2021-08-29

lilianxiang (审核中...)

前往app查看评论内容

#创新#

2021年8月27日简报：国产新冠灭活疫苗对德尔塔毒株保护率为59％；日本和越南疫情再创新高；美国发现未打疫苗者因新冠住院概率是已获保护者29倍

2021-08-28

科室
- - 订阅+
  - 更多科室
工具
服务